Phaseline

Companies › Lakewood-Amedex

Lakewood-Amedex: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nu-3
Topical antimicrobial gel
–Phase 2Diabetic Foot Ulcers (DFUs)Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07565506Nu-3Phase 2Diabetic Foot Ulcers (DFUs)Infectious diseaseJan 2027

From the company's SEC filings

Cash and short-term investments of $5m on 2026-06-30; operating cash outflow about $5m a year; runway about 11 months at that burn, to Jun 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

60 Degrees Pharmaceuticals Traws Pharma Acurx Pharmaceuticals Amplexd Therapeutics Sano Chemicals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.